Investing Profile

Michael Rome

VCInvestor
Managing Director & Co-Head of Therapeutics Investing at Foresite Capital
foresitecapital.com/people/mi...Los Angeles, California
Photo of Michael Rome, Managing Director at Foresite Capital
UCLA Network
34 CONNECTIONS
California Institute of Technology Network
16 CONNECTIONS
cb
Foresite Capital Managing Director
$100K - $5.0M
$1.5M
12
$668M
CompanyStageDateRound SizeTotal Raised
Alumis
Series CMar 2024$260M
Series AMay 2021$70M
$330M
Co-investors: Jim Tananbaum (Foresite Capital), Vikram Bajaj (Foresite Capital), Richard Gaster (venBio)
Remix Therapeutics
Series UnknownJan 2024$60M
Series BMay 2022$70M
Series ADec 2020$65M
$210M
Co-investors: Kevin Bitterman (Atlas Venture), Kristina Burow (ARCH Venture Partners), Leon Chen (The Column Group), Peter Svennilson (The Column Group)
CG Oncology
Series FAug 2023$110M
$110M
Co-investors: Shane Neman
XinThera
Series BAug 2021$50M
$50M
Co-investors: Carl Gordon (OrbiMed), Jim Tananbaum (Foresite Capital)
Theseus Pharmaceuticals
Series BApr 2021$100M
$100M
Co-investors: Carl Gordon (OrbiMed)
Kinnate Biopharma
Series CAug 2020$98M
Series BDec 2019$75M
Series AApr 2018$22M
$200M
Co-investors: Carl Gordon (OrbiMed), Brett Zbar (General Atlantic), Peter Kolchinsky (RA Capital)
Nurix Therapeutics
Private EquityMar 2020$120M
$150M
Co-investors: David Goeddel (The Column Group)
Office Assistant Impact Program for Prostate Cancer TreatmentPresent
Physical Sciences Tutor Los Angeles Valley CollegePresent
Lab Assistant and Researcher UCLAPresent
Research Associate in Microbiology UCLAPresent
Graduate Researcher in Biochemistry CaltechPresent
Scientist and Senior Scientist Vault PharmaPresent
Analyst DAFNA Capital Management, LLCPresent
Senior Analyst Foresite Capital ManagementPresent
California Institute of Technology Doctor of Philosophy (Ph.D.) Biochemistry, Biophysics and Molecular Biology
UCLA BS Molecular, Cellular and Developmental Biology